Evidence map›Paper›PMID 34327598›Full record

ReviewArchivum immunologiae et therapiae experimentalis2021

Stimulation of Innate and Adaptive Immune Cells with Graphene Oxide and Reduced Graphene Oxide Affect Cancer Progression.

Muhammad Amir Yunus, Muhammad Mahyiddin Ramli, Nurul Huda Osman, Rafeezul Mohamed

Abstract readReview
PubMed Publisher
In one paragraph

Review in Archivum immunologiae et therapiae experimentalis, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.0field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 19 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. [Immunogenic and toxic effects of graphene oxide nanoparticles in mouse skeletal muscles and human red blood cells].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2024
    Article
  8. Article
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Muhammad Amir YunusInfectomics Cluster, Advanced Medical and Dental Institute, Universiti Sains Malaysia, Bertam, 13200, Kepala Batas, Pulau Pinang, Malaysia.
Muhammad Mahyiddin RamliGeopolymer and Green Technology, Centre of Excellence (CEGeoGTech), Universiti Malaysia Perlis (UniMAP), Perlis, Malaysia.
Nurul Huda OsmanFaculty of Science, Department of Physics, Applied Electromagnetic Laboratory 1, Universiti Putra Malaysia, 43400, Serdang, Selangor, Malaysia.
Rafeezul MohamedRegenerative Medicine Cluster, Advanced Medical and Dental Institute, Universit Sains Malaysia, Bertam, 13200, Kepala Batas, Pulau Pinang, Malaysia. rafeezul@usm.my.
Universiti Sains Malaysia · MYUniversiti Malaysia Perlis · MYUniversiti Putra Malaysia · MY

Funding

Universiti Sains Malaysia (1001/CIPPT/8012205)
6 · The paper itself

Abstract

Sole nanomaterials or nanomaterials bound to specific biomolecules have been proposed to regulate the immune system. These materials have now emerged as new tools for eliciting immune-based therapies to treat various cancers. Graphene, graphene oxide (GO) and reduced GO (rGO) are the latest nanomaterials among other carbon nanotubes that have attracted wide interest among medical industry players due to their extraordinary properties, inert-state, non-toxic and stable dispersion in a various solvent. Currently, GO and rGO are utilized in various biomedical application including cancer immunotherapy. This review will highlight studies that have been carried out in elucidating the stimulation of GO and rGO on selected innate and adaptive immune cells and their effect on cancer progression to shed some insights for researchers in the development of various GO- and rGO-based immune therapies against various cancers.

Indexed as

GraphiteNanotubes, CarbonNeoplasmsHumansOxidesgraphene oxideGraphiteNanotubes, CarbonOxidesAdaptive immune cellsCancersGraphene oxideInnate immune cellsReduced graphene oxide

Identifiers

PMID34327598
OpenAlexW3186469028

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.